New York-based Pfizer and Germany-based BioNTech announced preliminary data from the most advanced of four vaccine candidates against SARS-CoV-2, the virus causing COVID-19.
If you are not happy with the results below please do another search
50 search results for:
Americans’ anxieties over the spread of the coronavirus are at the highest in more than a month, a Reuters/Ipsos poll showed on Wednesday, as California recorded the state’s largest single-day spike in cases since the pandemic began.
The U.S. Food and Drug Administration approved Bavencio (avelumab) for maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed after first-line platinum-containing chemotherapy.
A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.
This webinar will share information on the influence of multimillion-dollar pharmaceutical costs, along with successful cost containment practices demonstrated through case studies of effective intervention.
Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
The U.S. Food and Drug Administration issued guidelines for where the regulatory agency will set the bar for approval of a vaccine for COVID-19.
Amidst the pandemic, the biopharma industry continues to surge ahead as BioSpace reviews companies that have made recent job announcement expansions.
Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.
London-based Freeline announced the closing of a $120 million extended Series C financing to advance the company’s gene therapy programs, and is considering additional capital fundraising options during 2020.